Loading
HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Panobinostat, HDAC Inhibitor REC-2282, Vorinostat and Trichostatin A. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.34, clinical 0.95).
In plain words · HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.
HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
No product in this corpus aims at HDAC9 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA HDAC9: RNA low tissue specificity; blood lineage group enriched (B-cells 53 nTPM, dendritic cells 74 nTPM, monocytes 24 nTPM); no normal tissue stained high; highest cancer staining skin cancer (8 of 12 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Oesophageal cancer, Lymphoma, Multiple myeloma, Skin cancer (all types), Brain and spinal cord tumours (all types)); Open Targets associates it with 4 specific cancer types at or above 0.5 (plasma cell myeloma, peripheral T-cell lymphoma, not otherwise specified, mature T-cell and NK-cell non-Hodgkin lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9UKV0; CIViC gene HDAC9; Human Protein Atlas HDAC9 tissue; Open Targets ENSG00000048052 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 1998, "Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:14065 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UKV0 (protein name, function text, keywords and locations (REST API)); CIViC gene HDAC9 (3 evidence items, 0 assertions, 2 variants; diseases: Glioblastoma, Breast Cancer, Oesophageal Cancer (GraphQL API, CC0)); Open Targets ENSG00000048052 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: plasma cell myeloma 0.56, non-Hodgkin lymphoma 0.58, skin cancer 0.51, primary cutaneous T-cell non-Hodgkin lymphoma 0.51 (GraphQL API, CC0))
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription. Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Location: Nucleus (UniProt). Locus 7p21.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: group enriched (B-cells 53 nTPM, dendritic cells 74 nTPM, monocytes 24 nTPM).
No normal tissue stained high.
Medium only: breast cancer, carcinoid, cervical cancer, lung cancer.
HPA HDAC9 tissue · HPA HDAC9 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HDAC9" OR ABSTRACT:"HDAC9" OR TITLE:"histone deacetylase 9" OR ABSTRACT:"histone deacetylase 9" OR TITLE:"Histone deacetylase 9" OR ABSTRACT:"Histone deacetylase 9" OR TITLE:"KIAA0744" OR ABSTRACT:"KIAA0744" OR TITLE:"HD7" OR ABSTRACT:"HD7" OR TITLE:"HDAC7B" OR ABSTRACT:"HDAC7B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HDAC9, not a curated reading list.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types), CIViC, Non-Hodgkin lymphoma (all types).
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types), CIViC, Non-Hodgkin lymphoma (all types).
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Multiple myeloma, Non-Hodgkin lymphoma (all types).
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Non-Hodgkin lymphoma (all types).
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Non-Hodgkin lymphoma (all types).
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Non-Hodgkin lymphoma (all types).